JAK/STAT3 hyperactivation in tumor cells may occur as a result of elevated IL-6 levels in the serum and/or in the tumor microenvironment or loss-of-function mutations affecting negative regulators of STAT3 [75]. The gene discussed is IL6; the disease is neoplasm.